PPD ups capacity at vaccine development lab

(Image: PPD)

Pharmaceutical Product Development, LLC (PPD) has expanded its Richmond, Virginia-based vaccine sciences lab.

The global contract research organization (CRO) has added nearly 17,000 square feet of new vaccines laboratory space.

The Richmond-based operation now spans nearly 200,000 square feet.

The lab, which is part of PPD’s Richmond bioanalytical lab, offers various services to support vaccine development, including method development, qualification, and validation, as well as high-throughput, automated and/or multiplex assays. 

"The Richmond facility enables us to partner closely with our clients to deliver strong scientific and technical expertise across a broad range of highly customized services. This expansion is part of our ongoing efforts to meet the growing needs of our biopharmaceutical clients," Bob Nicholson, senior vice president of PPD Laboratories, told Outsourcing-Pharma.com.

"During the 30+ years we’ve had laboratory operations in Richmond, we’ve been able to successfully grow our operations there due in part to the strength of the talent in that region and the supportive business environment," he added. "We regularly evaluate all of our operations to make sure we are able to effectively and efficiently serve the needs of our clients."

Related News

(Image: iStock/ArtemSam)

PPD awarded for innovative eTMF development

The expanded PPD® Laboratories stability operation located at the company’s good manufacturing practices (GMP) lab in Middleton, Wisconsin. (Image: Pharmaceutical Product Development LLC)

PPD increases capacity, capabilities at Wisconsin-based GMP lab

GIC, Singapore’s sovereign wealth fund, and the Abu Dhabi Investment Authority to acquire minority ownership positions in PPD. (Image: iStock/anyaberkut)

PPD valued at more than $9bn as investors recapitalize